Journal article
Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion
R Buhl, E Bel, A Bourdin, I Dávila, JA Douglass, JM FitzGerald, DJ Jackson, NL Lugogo, A Matucci, ID Pavord, ME Wechsler, M Kraft
Journal of Allergy and Clinical Immunology in Practice | ELSEVIER | Published : 2022
Abstract
Severe asthma often remains uncontrolled despite effective treatments and evidence-based guidelines. A group of global experts in asthma and biologic medications from 9 countries considered the most relevant clinical variables to manage severe asthma in adult patients and guide treatment choice. The resulting recommendations address the investigation of biomarker levels (blood eosinophil count along with fractional concentration of exhaled nitric oxide [FeNO]), clinical features (oral corticosteroid [OCS] dependence, specific comorbid disease entities associated with severe type 2 asthma), and safety considerations. Current evidence suggests that biomarkers, including both blood or sputum eo..
View full abstractGrants
Funding Acknowledgements
The authors thank the advisors who participated in the advisory boards. They also thank Esther Garcia Gil (AstraZeneca, Barcelona, Spain) for leadership in the advisory board. Helios Medical Communications (Cheshire, United Kingdom) provided support for the advisors and advisory board. Writing and editing assistance, including preparation of a draft manuscript under the direction and guidance of the authors, incorporating author feedback, and manuscript submission, was provided by Wynne Dillon, MS (Kay Square Scientific, Newtown Square, Pa) and Esther Garcia Gil, MD (AstraZeneca, Barcelona, Spain). This support was funded by AstraZeneca.